Novavax's COVID vaccine gets FDA approval, but with limits
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter.
Novavax has at last gained full Food and Drug Administration approval for its COVID-19 vaccine, but the OK comes with limitations not specified for other COVID shots available in the U.S.
Dubbed Nuvaxovid, the vaccine is cleared for use in people 65 years and older as well as for individuals between 12 and 64 years who have an underlying condition that puts them at higher risk of severe disease.
The vaccine, which uses an older protein technology than the mRNA shots of Pfizer and Moderna, has been available in the U.S. since 2022 under emergency use authorization.
While narrower, the approved indication is no more restrictive than what Leerink Partners analyst Daina Graybosch expects advisers to Centers for Disease Control and Prevention will recommend next month. In an April meeting, a panel of those advisers discussed adjusting their recommendations for COVID vaccination.
News of the FDA's approval send Novavax shares higher by double digits Monday.
"Market research and U.S. CDC statistics indicate that older individuals and those with underlying conditions are the populations most likely to seek out COVID-19 vaccination seasonally,' Novavax CEO John Jacobs said in a statement. 'This significant milestone demonstrates our commitment to these populations and is a significant step towards availability of our protein-based vaccine option.'
An FDA approval deadline for Novavax's shot came and went last month, as reports indicated new leaders at the FDA had intervened in the agency's review of the company's application.
The FDA is requiring Novavax conduct a new placebo-controlled 'Phase 4' trial to assess Nuvaxovid's safety and efficacy in people aged 50 to 64 years who are not at high risk. Late-stage testing in 2021 showed the shot to be roughly 90% effective, but Commissioner Martin Makary questioned whether that data remains relevant today, writing on the social media platform X that 'new products require new clinical studies.'
The added requirement comes as vaccines more broadly get closer scrutiny under Health and Human Services Secretary Robert F. Kennedy Jr., who has for years objected to U.S. vaccination policies. The agency recently said all new vaccine applications must include data from placebo-controlled trials before approval.
Novavax's commitments won't restrict a commercial launch for the upcoming fall and winter seasons, according to Jefferies analyst Roger Song, who wrote in a client note that he sees the approval as a win for the company. Novavax said its ready to deliver the shot in the fall pending strain recommendations from an FDA advisory panel that's set to meet later this week.
The approval triggers a milestone payment of $175 million from Novavax's partner Sanofi, which signed a licensing deal last year.
Recommended Reading
CDC panel mulls changes to COVID shot recommendations
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
The reasons aren't fully clear, but overdose deaths are down in Kern, US
Overdose deaths, specifically from opioids, are on the decline across the nation and data from the Kern County Coroner's Office shows local deaths are down as well. According to KCSO, there were 189 fentanyl-related overdose deaths in Kern County in 2024, down from 297 in 2023, a roughly 36% decline. The decline is part of a broader trend nationally. Opioid overdose deaths declined sharply from 2023-2024, according to provisional data from the Centers for Disease Control and Prevention. According to the CDC, 48 states and the District of Columbia all saw decreases in overdose deaths from December 2023 to 2024, a 26% decrease nationwide. California's reported overdose deaths dropped by 24%, the most of any West Coast state. Only Nevada and South Dakota saw an increase in overdose deaths, both by less than 4%. It's not entirely clear what's driving the decline, and experts are pointing to a range of factors. "Over the past, I'd say this calendar year, we have seen an increase in the people who are coming into our treatment system," said Ana Olvera, an administrator with Kern Behavioral Health and Recovery Services. "More people have accessed our treatment system than in years past, even coming out of COVID, which is a good sign for us," Olvera said. The increased availability of treatment programs and the overdose reversal drug naloxone were likely contributors to the decrease, she said, as well as reduced stigma about seeking treatment. Olvera also pointed to the passage of Proposition 36, which increased penalties for certain crimes. "Just from that — working with the courts and people who are eligible for this program that have a treatment-mandated felony — we have seen an increase of folks who are eligible and who come into our system of care," Olvera said. BHRS and other health care providers have increased their treatment options, Olvera said. The county's 24-hour substances-use-disorder hotline, which helps connect people with treatment, has seen higher call volume over the years, she said. "The call center is how most people access treatment in our substance use system," Olvera said. The average number of calls has increased from 908 in the 2018-2019 fiscal year to 1,272 in 2023-2024. From July 2024 to April of this year, there were 1,061 calls. There's no doubt overdose deaths are dropping, but exactly why is still a matter of conjecture. The Opioid Data Lab at the University of North Carolina at Chapel Hill tracks information related to opioids and its researchers have said there's no single explanation for such a steep, nationwide decline in overdose deaths. "Ascribing a single national explanation for the drop in overdoses is not grounded in data," the lab said in a February analysis. Even with the large decline in deaths, the mortality rate from drug overdoses remains high, with most states still recording death rates higher than before the COVID-19 pandemic. Data from the CDC and the California Department of Public Health shows overdose deaths peaking in 2023 before dropping sharply in 2024. According to CDPH, Kern County's opioid-related overdose deaths reached an all-time high of 321 in 2023. That was up from 308 in 2022 and 274 in 2021. As of April 30, Kern had seen 50 fentanyl-related deaths so far this year, according to KCSO.
Yahoo
an hour ago
- Yahoo
RFK Jr.'s HHS Shakeup Spares Dr. Plescia, Backer Of Vaccine Credentials
Despite firing every member of the federal vaccine advisory committee, Health and Human Services Secretary Robert F. Kennedy Jr. has retained one key figure with a radically pro-passport past. Kennedy, who recently disbanded the Advisory Committee on Immunization Practices (ACIP), kept Dr. Marcus Plescia in a top post at HHS as Deputy Assistant Secretary and Director of the Office of Science and Medicine. Plescia's past comments in favor of vaccine passports place him well to the left of even the Biden White House's stance during the height of the COVID-19 pandemic. In 2021, Plescia — then serving as chief medical officer for the Association of State and Territorial Health Officials — told The New York Times that vaccine passport credentials were 'going to be necessary,' calling it 'perplexing' that the federal government was keeping its distance from such a proposal. His remarks came even as White House Press Secretary Jen Psaki assured reporters that 'there will be no federal vaccinations database and no federal mandate requiring everyone to obtain a single vaccination credential.' Plescia's position, made public at the time through The New York Times' reporting, stood in contrast not only to Biden's hesitancy but also to an ongoing wave of state-level opposition. Governors from Texas, Florida, and Mississippi issued orders banning or opposing any form of vaccine credentialing, arguing it violated basic liberties and privacy. Kennedy's implicit decision to retain contrasts with his other decisions. On June 9, the new health secretary made headlines for his sweeping removal of the 17-member ACIP panel, citing what he called a 'crisis of public trust' caused by conflicts of interest and pharmaceutical industry influence. 'The committee has become… little more than a rubber stamp for any vaccine. It has never recommended against a vaccine—even those later withdrawn for safety reasons.' Kennedy wrote in an op-ed for The Wall Street Journal, adding that many members had received 'substantial funding from pharmaceutical companies.' But the retention of Plescia — whose support for vaccine passports predates the Biden administration's relatively more cautious approach — raises questions. Plescia's 2021 endorsement of vaccine credentials aligned more with European-style digital health passes and apps like those trialed by Cathay Pacific Airlines and implemented by companies such as Walmart. 'There is going to have to be some kind of system where [vaccination status] is verified,' he said, arguing it was the only way to safely reopen businesses and restore public trust. The White House was unwilling to go that far at the time, concerned about the ethical implications and civil liberties involved. Instead, Psaki emphasized the government's position that any such system should 'meet key standards, including accessibility, affordability and privacy,' but would ultimately be left to the private sector. President Biden never fully implemented a vaccine passport system, but he did issue an executive order requiring nearly every private sector employee to get the COVID shot, which in turn prompted companies to create systems of verification for employees and customers. RFK Jr., a longtime COVID vaccine critic, ran a presidential campaign and later accepted his appointment to HHS on promises to dismantle what he called medical 'fascism.' His decision to purge the ACIP panel came after immense pressure from MAHA allies, including Dr. Mary Talley Bowden of Houston, who slammed the secretary for not taking more aggressive policy action to date, The Dallas Express reported. Kennedy's shakeup alarmed some congressional figures. Sen. Bill Cassidy (R-LA), a physician, said, 'Of course, now the fear is that the ACIP will be filled up with people who know nothing about vaccines except suspicion. I've just spoken with Secretary Kennedy, and I'll continue to talk with him to ensure this is not the case.' Kennedy was contacted for comment in the production of this story, but he did not respond. A spokesman for HHS did not immediately respond. Plescia's HHS bio describes his duties as follows: 'He advises the Assistant Secretary and OASH leadership across scientific and medical issues covering the full suite of public health priorities. He oversees staff and program work focused on state and federal health systems, infection-associated chronic conditions, vector borne disease, data-driven decision making and healthcare innovation.' The bio qualifies him for the job by saying, '[He] has widespread experience in medicine and public health. He is Board Certified in Family Medicine and practiced for over 20 years in a variety of settings serving homeless, urban poor and rural underserved populations.'
Yahoo
3 hours ago
- Yahoo
There's a new blood test for Alzheimer's. Here's everything you need to know.
When you buy through links on our articles, Future and its syndication partners may earn a commission. The U.S. Food and Drug Administration (FDA) recently cleared a blood test that detects signs of Alzheimer's disease in the brain, according to multiple studies. This is the first-ever blood test available for this common form of dementia. Here's how the new blood test works and why it could be useful to patients. Alzheimer's disease is on the rise, in part because the age group most prone to dementia is growing larger. In the U.S., an estimated 7.2 million Americans ages 65 and older are living with Alzheimer's dementia in 2025. The percentage of affected people increases with age: About 5% of people ages 65 to 74 have Alzheimer's, compared with more than 33% of people ages 85 and older. At the point when a doctor has verified that a patient has cognitive decline, the blood test can be used in place of standard tests to see if they likely have Alzheimer's. Previously, gold-standard methods of diagnosing Alzheimer's have been more invasive and expensive, involving positron emission tomography (PET) scans, which use radioactive substances; and lumbar punctures, (also called spinal taps) during which a clinician uses a needle to sample spinal fluid from the low back. Clinicians also sometimes use MRIs or CT scans to rule out other causes of cognitive decline. The new test measures the ratio of two proteins in human blood, and this ratio correlates with the presence or absence of amyloid plaques, a primary sign of Alzheimer's found in the brain. For people experiencing memory lapses that might be due to Alzheimer's, the first step is to see their primary care physician (PCP), who should do a cognitive test. If there are signs of cognitive impairment, the patient would then be referred to a neurologist for an in-depth evaluation. Both dementia specialists and PCPs will be able to order this blood test to help with diagnosis, said Dr. Gregg Day, a neurologist with the Mayo Clinic in Jacksonville, Florida; Day led a study of the blood test published in June in the Journal of the Alzheimer's Association. A study published in 2024 in JAMA found that whether the test was ordered by a PCP or specialist, it was equally accurate at confirming suspected Alzheimer's diagnoses. PCPs could use the test results to decide whether to refer patients to a specialist, who could prescribe treatments such as lecanemab or donanemab, Day said. Or the PCP could personally prescribe a medicine like donepezil, which can help improve mental function in Alzheimer's. With FDA clearance, Medicare and private health insurance providers alike are expected to cover the new blood test, Day said. The test — called the "Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio" — is intended for people ages 55 and older who show signs and symptoms of cognitive decline that have been confirmed by a clinician. The test is designed for the early detection of amyloid plaques associated with Alzheimer's disease. (Amyloid plaques are unusual clumps found between brain cells and made up of a type of protein called beta-amyloid.) Related: Man nearly guaranteed to get early Alzheimer's is still disease-free in his 70s — how? Early detection is important, said Dr. Sayad Ausim Azizi, clinical chief of behavioral neurology and memory disorders at the Yale School of Medicine. That's because the Alzheimer's brain is like a rusty engine — the plaque is like rust settling onto the engine, interfering with the wheels' ability to turn, Azizi told Live Science. There are FDA-approved treatments that act like oil, helping the wheels to turn, but the medication does not remove the rust itself, he said. Available therapies can slow down the degradation of the brain by about 30% to 40%, studies show, so the patient can retain function for longer. "If you're driving now and living independently and you don't take the medicine, it's likely in five years you won't be able to do all these things," Azizi said, providing a hypothetical example. "If you take the medicine, the five years are extended to eight." If adopted as intended, the new blood test could help more people access these treatments sooner. The test is not recommended for the purposes of screening the general population. It is intended only for people who have been found by a doctor to exhibit signs of Alzheimer's disease, Day and Azizi emphasized. Some amount of amyloid is present in the brain during healthy aging, so its presence doesn't guarantee someone will later have Alzheimer's. If the test detects signs of amyloid plaques 20 years before any cognitive symptoms surface, Azizi explained, it would not make sense to treat the patient at that time. "The treatments are not 100% benign," he added. To receive lecanemab, for example, patients must be able to receive an infusion every two weeks at first and every four weeks later on; donanemab is given every four weeks. Both medications can come with infusion-related reactions, such as headache, nausea and vomiting. Rarely, the treatment donanemab can cause life-threatening allergic reactions, and both lecanemab and donanemab have been tied to rare cases of brain swelling or bleeding in the brain. These latter side effects are related to "amyloid-related imaging abnormalities," which are structural abnormalities that appear on brain scans. The new test can give false positives, meaning a person can potentially test positive when they don't actually have Alzheimer's. That's because the signs of amyloid that the tests look for can be tied to other conditions. For instance, amyloid buildup in the brain could be a sign the kidneys are not functioning optimally, Day said, so he recommends also doing a blood test for kidney function when ordering the Alzheimer's blood test. The Mayo Clinic study included about 510 people, 246 of whom showed cognitive decline; the blood test confirmed 95% of those with cognitive symptoms had Alzheimer's. About 5.3% of cases showed a false negative on the blood test, while 17.6% of cases gave a false positive, Day said. Most of the false-positive patients still had Alzheimer's-like changes in their brains, but their symptoms were ultimately attributed to other diseases, such as Lewy body dementia, Day said. The Mayo study found that the blood test helped doctors distinguish Alzheimer's from these other forms of dementia. As is true of many clinical trials, evaluations of the test have primarily included populations that are healthier than average, Day said. These individuals are not only healthier at baseline, but are more likely to have health insurance and be white and non-Hispanic. So when the blood test is used in a broader population, there may be people with sleep apnea or kidney disease who test positive despite not having Alzheimer's, Day said. Some people with these health problems may also experience memory issues or cognitive impairment that's not caused by Alzheimer's disease. If the blood test points to amyloid buildup, doctors could order additional tests and ask patients about their sleep to help rule out these other possibilities. RELATED STORIES —Could vaccines prevent and treat Alzheimer's disease? —Study unravels whole new layer of Alzheimer's disease —Alzheimer's comes in at least 5 distinct forms, study reveals The test will give researchers a more precise idea of how a patient's clinical symptoms relate to the findings on their blood test, Azizi said. "It's a great way of using a biomarker [measurable sign of disease] in the blood to make an earlier diagnosis to give a drug" to slow disease progression, he said. Azizi added that this blood test could help track whether a treatment for Alzheimer's disease is working, which would be useful both for patients receiving approved medicines and those in trials of new drugs. Looking forward, researchers will also be able to evaluate how well blood-based testing works in more diverse populations, Day noted. This article is for informational purposes only and is not meant to offer medical advice.
